Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Strul, H.
Right arrow Articles by Arber, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strul, H.
Right arrow Articles by Arber, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:51-56, 2002
© 2002 European Society for Medical Oncology

Debate

Fecal occult blood test for colorectal cancer screening

H. Strul and N. Arber,+

Gastro-intestinal Oncology Unit, Department of Gastroenterology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

Received 17 September 2001; accepted 10 October 2001.

Key words: colorectal cancer, fecal occult blood test, screening

Introduction

Colorectal cancer (CRC) is a major health concern and a leading cause of cancer death in the Western world. The estimated lifetime risk of CRC is 5% to 6%, the incidence rate increases sharply after the age of 50. Approximately 75% of new cases occur in individuals at average risk [1, 2]. Worldwide, it is estimated that there will be over one million new CRC cases in the year 2001 (personal communication), and the annual age-adjusted incidence rate is 57 per 100 000. Survival is directly related to the extent of disease at the time of diagnosis. Those diagnosed at an advanced stage have an estimated 5-year survival rate of 7%, in contrast with a survival rate of 92% for individuals detected at an early stage, since advanced CRC is largely refractory to conventional therapy and is one of the least curable malignancies [3]. Despite continuing . . . [Full Text of this Article]

Rationale of the test

Sensitivity, specificity and positive predictive value

Cost-effectiveness of FOBT

Disadvantages

Stool testing merits further consideration

Discussion

Acknowledgements

Footnotes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al.
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Ann. Onc., April 1, 2006; 17(4): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, et al.
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
J. Clin. Oncol., July 1, 2005; 23(19): 4265 - 4274.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Boyle, H. Vainio, R. Smith, R. Benamouzig, W. C. Lee, N. Segnan, K. Takima, and Y. Tsubono
Workgroup I: criteria for screening. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)
Ann. Onc., January 1, 2005; 16(1): 25 - 30.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Boyle
Screening
Eur. Respir. J., January 1, 2003; 21(39_suppl): 3S - 15s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Boyle
Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy
Ann. Onc., January 19, 2002; 13(1): 16 - 18.
[Full Text] [PDF]